Special Issue "Advances in Breast Cancer Research: From Biology to Pathology"
Deadline for manuscript submissions: 31 August 2022.
Interests: tumor signaling; primary cells; cancer-associated fibroblasts; endogenous retroelements; innate immunity; 3D cell-migration
Interests: breast pathology; breast cancer; molecular subtyping; predictive biomarker; targeted therapy; gynecopathology
Breast cancer represents histological and molecular tumor subtypes, including luminal, basal, claudin-low, HER2-enriched, and unclassified subtypes stemming from different cellular origins and/or somatic changes, which are essential for the diagnosis and prediction of patient survival and therapy. Understanding the biology of non-neoplastic breast parenchyma as well as breast cancer will lead to better understandings of carcinogenesis and metastases, where both involve essential interaction with the tumor immune microenvironment. Uniting both the biological and pathological contexts of breast cancer will enable us to identify further targets for the development of more precise therapies in the future.
We are pleased to invite you to submit research papers, reviews, communications, etc., for this Special Issue of Cancers, “Advances in Breast Cancer Research: from Biology to Pathology”. Cancers encourages authors to publish experimental and theoretical results in as much detail as possible, which also include studies showing meaningful but negative results. We invite high-quality articles including basic, translational, and clinical studies on breast normal and tumor biology and pathology.
This Special Issue aims to strengthen interdisciplinary networking between molecular and cellular biology and pathology in order to accelerate translational research for breast cancer. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- biology of non-neoplastic breast parenchyma and pathology of breast cancer;
- histological and molecular tumor subtypes, prognosis and therapy;
- tumor immune microenvironment including extracellular matrix of breast and breast cancer along with immune cell interactions;
- primary normal and cancer cells including cancer-associated fibroblasts (CAFs) and adipose stem cells ;
- plasticity from epithelial to mesenchymal (EMT) or amoeboid (EAT) cell types;
- biomarkers and their regulation, including epigenetics;
- structural cell changes and biophysics of breast cell migration.
We look forward to receiving your contributions.
Prof. Dr. Reiner Strick
Dr. Ramona Erber
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- ductal and lobular
- triple negative
- cancer associated fibroblast (CAF)
- steroid hormone receptors
- prognostic factors
- predictive biomarkers